The content on this site is intended for healthcare professionals only

Breast

Prostate & urology

Lung & pleura

Colorectal & gastro

Melanoma & skin

Head & neck

Ovary & gynaecology

+ -

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Biomarker guidance allows patients 55 or older with low-grade luminal A-type bre...

Dr Timothy J. Whelan - McMaster University, Ontario, Canada

Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy ( Dr Timothy J. Whelan - McMaster University, Ontario, Canada )

Comment: Biomarker guidance allows patients 55 or older with low-grade luminal A...

Dr Bishal Gyawali - Queen's University, Kingston, Canada

Comment: Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patient...

Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio,...

Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patients previously treated with a JAK inhibitor ( Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )

Luminal A-type breast cancer patients with low levels of the Ki67 biomarker can ...

Dr Timothy J. Whelan - McMaster University, Ontario, Canada

Luminal A-type breast cancer patients with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy ( Dr Timothy J. Whelan - McMaster University, Ontario, Canada )

ASCO 2022: Panel discussion on bladder preservation

Dr Petros Grivas, Prof Rob Jones, Prof Phil Cornford and Prof Kurt Miller

ASCO 2022: Panel discussion on bladder preservation ( Dr Petros Grivas, Prof Rob Jones, Prof Phil Cornford and Prof Kurt Miller )

Pembrolizumab demonstrates clinically meaningful improvement in distant metastas...

Dr Georgina Long - The University of Sydney, Sydney, Australia

Pembrolizumab demonstrates clinically meaningful improvement in distant metastasis-free survival in patients with melanoma ( Dr Georgina Long - The University of Sydney, Sydney, Australia )

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer wi...

Dr Virginia G. Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San ...

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer without prior chemotherapy patients ( Dr Virginia G. Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )

ASCO 2022: Latest in prostate cancer, including PARP inhibitors

Dr Neal Shore, Prof Cora Sternberg, Prof Eleni Efstathiou and Prof Phil Cornford

ASCO 2022: Latest in prostate cancer, including PARP inhibitors ( Dr Neal Shore, Prof Cora Sternberg, Prof Eleni Efstathiou and Prof Phil Cornford )

Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard of...

Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands

Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard of care for resectable stage III melanoma ( Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands )

Pancreatic neuroendocrine tumours: Capecitabine plus temozolomide gives longer P...

Dr Pamela Kunz - Yale Cancer Center, New Haven, USA

Pancreatic neuroendocrine tumours: Capecitabine plus temozolomide gives longer PFS than temozolomide alone ( Dr Pamela Kunz - Yale Cancer Center, New Haven, USA )

ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal strom...

Dr César Serrano - Vall d'Hebron Institute of Oncology, Barcelona, Spain

ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal stromal tumour ( Dr César Serrano - Vall d'Hebron Institute of Oncology, Barcelona, Spain )

FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-ty...

Dr Chiara Cremolini - University of Pisa, Pisa, Italy

FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-type mCC ( Dr Chiara Cremolini - University of Pisa, Pisa, Italy )

More from ecancer